Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China , Aug. 10, 2022 |PRNewswire| -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary endpoint was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 study (clinicaltrials.gov, NCT 05003531) of picankibart (RD code: IBI112), a recombinant anti-interleukin 23p19 subunit antibody injection, in Chinese patients with moderate-to-severe plaque psoriasis. This study (CIBI112A201) was designed to evaluate the efficacy and safety of picankibart under various administration in the treatment of moderate-to-severe plaque psoriasis. A total of 250 subjects were randomized 1:1:1:1:1 to receive 50 mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 8 weeks), 200mg (once at week 0, 4, then every 12 weeks) of picankibart or placebo.
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China , Aug. 10, 2022 |PRNewswire| -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary endpoint was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 study (clinicaltrials.gov, NCT 05003531) of picankibart (RD code: IBI112), a recombinant anti-interleukin 23p19 subunit antibody injection, in Chinese patients with moderate-to-severe plaque psoriasis. This study (CIBI112A201) was designed to evaluate the efficacy and safety of picankibart under various administration in the treatment of moderate-to-severe plaque psoriasis. A total of 250 subjects were randomized 1:1:1:1:1 to receive 50 mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 8 weeks), 200mg (once at week 0, 4, then every 12 weeks) of picankibart or placebo.